{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-063316","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-09-24T11:05:32+00:00","discovered_at":"2026-09-24T11:30:10.336412+00:00","generated_at":"2026-09-24T11:35:21.987851+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vistagen reports positive fasedienol data in very severe social anxiety at Psych Congress 2026","bullets":["Post-hoc PALISADE-4 Phase 3 analysis showed statistically significant SUDS improvement in very severe SAD (LSAS >=95) despite missed primary endpoint in overall population.","Phase 2a repeat-dose study prespecified analysis: significant SUDS improvement after single dose; greater numerical improvement after second dose taken 10 minutes later.","Second-dose data also showed significant improvements in anticipatory anxiety pre-PSC in both overall and very severe populations.","Safety in very severe subgroup consistent with prior trials; no serious drug-related signals identified.","Data presented at Psych Congress 2026 in New Orleans; supports fasedienol's potential for LSAS >=95 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-063316","json":"https://secwatch.observer/filing/0001628280-26-063316.json","markdown":"https://secwatch.observer/filing/0001628280-26-063316.md","text":"https://secwatch.observer/filing/0001628280-26-063316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026063316/0001628280-26-063316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026063316/vtgn-20260924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-24T11:35:21.987851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}